Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first half of 2025, continuing a trend of decreasing performance that began last year [2][3] Financial Performance - In the first half of 2025, the company achieved revenue of approximately 413 million yuan, a year-on-year decrease of 21.08% [2] - The net profit attributable to shareholders was a loss of approximately 92.39 million yuan, a year-on-year decrease of 451.68% [2] - For the full year of 2024, the company reported revenue of 1.132 billion yuan, down 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [4][5] Core Business Segment - The pharmaceutical segment, which is the core business, faced significant revenue pressure, generating sales of 356 million yuan in the first half of 2025, a decline of 24.25% year-on-year, accounting for 86.08% of total revenue [3][4] - Revenue from infusion products was 132 million yuan, down 12.14% year-on-year [4] - Non-infusion products saw growth in sales due to successful bidding in centralized procurement, but the revenue from small-volume injectables dropped by 37.91% due to a 56.85% price reduction on a key product [4] New Business Segments - The animal health and wellness sectors, which the company has been focusing on, have not yet become significant contributors to revenue and are still in the investment phase [6] - Revenue from functional foods, cosmetics, veterinary drugs, and feed additives accounted for only 7.21% of total revenue in 2024 [7] Subsidiary Performance - The company’s two wholly-owned subsidiaries, Lanxi Pharmaceutical and Lingbao Sanlian, contributed to the overall losses [8] - Lanxi Pharmaceutical reduced sales to the parent company due to previous stockpiling of raw materials, leading to a significant drop in revenue [8] - Lingbao Sanlian, in its initial phase, reported negative profit margins and increased depreciation costs after reaching operational status [8]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first half of 2025, continuing a trend of decreasing performance that began last year [1][2]. Revenue and Profit Summary - In the first half of 2025, the company achieved revenue of approximately 413 million yuan, a year-on-year decrease of 21.08%. The net profit attributable to shareholders was a loss of approximately 92.39 million yuan, a year-on-year decrease of 451.68% [1][2]. Core Business Performance - The pharmaceutical segment, which is the core business of the company, faced significant revenue pressure, resulting in a sales income of 356 million yuan, a year-on-year decline of 24.25%, accounting for 86.08% of total revenue [2][4]. - The infusion products generated sales revenue of 132 million yuan, down 12.14% year-on-year. Non-infusion products saw growth in sales volume due to successful bidding in centralized procurement, but the revenue from small-volume injectables dropped by 37.91% due to a 56.85% price reduction on a key product [3][4]. Financial Trends - The company's 2024 annual report indicated that the pharmaceutical segment's revenue was approximately 989 million yuan, a year-on-year decrease of 13.48%, representing 87.34% of total revenue. The report highlighted the impact of centralized procurement on revenue and profit [4]. - In the first quarter of 2025, the company transitioned from profit to loss, with revenue of 205 million yuan, a year-on-year decline of 16.93%, and a net profit of -28.84 million yuan, a decrease of 253.52% [3][4]. New Business Segments - The animal health and wellness sectors, which the company has been focusing on, have not yet become a significant revenue driver and are still in the investment phase, leading to increased operational costs without substantial revenue generation [5]. - The combined revenue from functional foods, cosmetics, veterinary drugs, and feed additives accounted for only 7.21% of total revenue in 2024 [5]. Subsidiary Performance - The company's two wholly-owned subsidiaries, Lanxi Pharmaceutical and Lingbao Sanlian, contributed to the overall losses. Lanxi Pharmaceutical reduced sales to the parent company due to previous stockpiling, while Lingbao Sanlian, in its early stages, reported negative profit margins and increased depreciation costs [6][7].

Core Points - The company, Harbin Sanlian Pharmaceutical Co., Ltd., has released its 2025 semi-annual report, which includes important financial and operational information [1][15]. - The board of directors and the supervisory board have both approved the semi-annual report and related documents, confirming that the information disclosed is true, accurate, and complete [24][26]. Group 1: Board Meeting - All directors attended the board meeting that reviewed the semi-annual report [2][11]. - The meeting was held on August 25, 2025, and all 9 directors participated in the voting process [10][12]. - The board approved the proposal regarding the 2025 semi-annual report with unanimous support [13][14]. Group 2: Supervisory Board Meeting - The supervisory board meeting was also held on August 25, 2025, with all 3 supervisors present [21][22]. - The supervisory board confirmed that the procedures for preparing and reviewing the semi-annual report complied with relevant laws and regulations [24]. - The board approved the proposal regarding the use of raised funds, stating that there were no violations or misuses of the funds [26].

哈尔滨三联药业股份有限公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：哈尔滨三联药业股份有限公司 单位：万元 | 其他关联资金往来 | 资金往来方名称 | 往来方与上 市公司的关 | 上市公司核 | 2025年期 | 2025半年度 往来累计发生 | 2025半年度 | 2025半年度 | 2025半年度 | | 往来性质（经营 性往来、非经营 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 算的会计科 | 初往来资 | 金额（不含利 | 往来资金的利 | 偿还累计发生 | 期末往来资金 | 往来形成原因 | | | | | 联关系 | 目 | 金余额 | 息） | 息（如有） | 金额 | 余额 | | 性往来） | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | | 兰西哈三联制药有限公司 | 控股子公司 | 其他应收款 | 107.29 | 747.58 | | - | 854.87 ...

哈尔滨三联药业股份有限公司 2025 年半年度财务报告 哈尔滨三联药业股份有限公司 2025 年半年度财务报告 （未经审计） 2025 年 8 月 1 | 一、审计报告 | 3 | | --- | --- | | 二、财务报表 | 3 | | 三、公司基本情况 20 | | | 四、财务报表的编制基础 21 | | | 五、重要会计政策及会计估计 21 | | | 六、税项 | 42 | | 七、合并财务报表项目注释 43 | | | 八、研发支出 82 | | | 九、合并范围的变更 85 | | | 十、在其他主体中的权益 88 | | | 十一、政府补助 93 | | | 十二、与金融工具相关的风险 95 | | | 十三、公允价值的披露 97 | | | 十四、关联方及关联交易 99 | | | 十五、股份支付 105 | | | 十六、承诺及或有事项 106 | | | 十七、资产负债表日后事项 106 | | | 十八、其他重要事项 107 | | | 十九、母公司财务报表主要项目注释 108 | | | 二十、补充资料 118 | | 哈尔滨三联药业股份有限公司 2025 年半年度财务报告 一、 ...

Group 1 - The company Hasi Lian (SZ 002900) held its 23rd meeting of the fourth board of directors on August 25, 2025, via telecommunication voting, discussing the proposal for the 2025 semi-annual report [1] - For the year 2024, Hasi Lian's revenue composition is as follows: pharmaceutical industry 87.34%, veterinary medicine 6.64%, other businesses 5.44%, cosmetics 0.45%, and functional foods 0.12% [1] - As of the report date, Hasi Lian's market capitalization is 4.7 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

格隆汇8月26日丨哈三联(002900.SZ)公布2025年半年度报告，上半年公司实现营业收入4.13亿元，同比 下降21.08%；归属于上市公司股东的净利润-9239.04万元，同比盈转亏；归属于上市公司股东的扣除非 经常性损益的净利润-8919.59万元；基本每股收益-0.29元。 ...

哈三联(002900.SZ)发布2025年半年度报告，报告期内，公司实现营业收入4.13亿元，同比下降21.08%。 归属于上市公司股东净亏损9239.04万元。归属于上市公司股东的扣除非经常性损益净亏损8919.59万 元。基本每股亏损0.29元。 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-047 哈尔滨三联药业股份有限公司 2025 年半年度募集资金存放与使用情况专项报告 一、募集资金基本情况 经中国证券监督管理委员会许可[2017]1602 号文核准，并经深圳证券交 易所同意，本公司由主承销商安信证券股份有限公司于 2017 年 9 月 12 日 向社会公众公开发行普通股（A 股）股票 5,276.67 万股，每股面值 1 元， 每股发行价人民币 18.07 元。截至 2017 年 9 月 18 日止，本公司共募集资金 953,494,269.00 元 ， 扣 除 发 行 费 用 53,375,312.82 元 ， 募 集 资 金 净 额 900,118,956.18 元。 截至 2017 年 9 月 18 日，本公司上述发行募集的资金已全部到位，业 经大华会计师事务所（特殊普通合伙）以"大华验字[2017]000685 号"验资报 告验证确认。 截至 2025 年 6 月 30 日，公司对募集资金项目累计投入 780,143,509.34 元，其中：公司于募集资金到位之前利用自有资金先期投入募集资金项目 人民币 126,881, ...

证券代码：002900 证券简称：哈三联 公告编号：2025-044 哈尔滨三联药业股份有限公司 第四届监事会第十八次会议决议公告 经审核，监事会认为董事会编制和审议公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的相关规定，报告内容真实、准确、完整地反映了 上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决情况：有效表决 3 票，同意 3 票；反对 0 票；弃权 0 票。 一、监事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下简称"公司"）第四届监事会第十八 次会议通知以电子邮件及微信方式于 2025 年 8 月 15 日发出。 2、本次会议于 2025 年 8 月 25 日在公司会议室以现场表决方式召开。 3、本次会议应到监事 3 人，实际出席并表决的监事 3 人。 4、公司监事会主席翟玉平先生主持了会议。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、监事会会议审议情况 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述 ...